It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Menstrual blood-derived stromal cells (MenSCs) are emerging as a strong candidate for cell-based therapies due to their immunomodulatory properties. However, their direct impact on innate immune populations remains elusive. Since macrophages play a key role in the onset and development of inflammation, understanding MenSCs implication in the functional properties of these cells is required to refine their clinical effects during the treatment of inflammatory disorders. In this study, we assessed the effects that MenSCs had on the recruitment of macrophages and other innate immune cells in two mouse models of acute inflammation, a thioglycollate (TGC)-elicited peritonitis model and a monobacterial sepsis model. We found that, in the TGC model, MenSCs injection reduced the percentage of macrophages recruited to the peritoneum and promoted the generation of peritoneal immune cell aggregates. In the sepsis model, MenSCs exacerbated infection by diminishing the recruitment of macrophages and neutrophils to the site of infection and inducing defective bacterial clearance. Additional in vitro studies confirmed that co-culture with MenSCs impaired macrophage bactericidal properties, affecting bacterial killing and the production of reactive oxygen intermediates. Our findings suggest that MenSCs modulate the macrophage population and that this modulation must be taken into consideration when it comes to future clinical applications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Universidad de Granada, Unidad de Inmunología, IBIMER, CIBM, Granada, Spain (GRID:grid.4489.1) (ISNI:0000000121678994)
2 Universidad de Granada, Departamento de Bioquímica y Biología Molecular III e Inmunología, Facultad de Medicina, Granada, Spain (GRID:grid.4489.1) (ISNI:0000000121678994); Hospital Universitario Clínico San Cecilio, Unidad de Gestión Clínica Laboratorios, Granada, Spain (GRID:grid.459499.c)
3 Universidad de Granada, Unidad de Inmunología, IBIMER, CIBM, Granada, Spain (GRID:grid.4489.1) (ISNI:0000000121678994); Universidad de Granada, Departamento de Bioquímica y Biología Molecular III e Inmunología, Facultad de Medicina, Granada, Spain (GRID:grid.4489.1) (ISNI:0000000121678994)




